Clinical research digest — bremelanotide / melanocortin agonist
PT-141 is the only melanocortin desire drug a regulator has actually approved — for one group, with one dose, on one label.
A measured, plain-English reading of what the trials measured, what the label permits, and how access to a prescription sexual-health therapy actually works.
The short version
PT-141 is the lab name for bremelanotide, a small peptide (a short chain of amino acids) that works in the brain to nudge sexual desire. In 2019 the US Food and Drug Administration (FDA) approved it for one specific use: low sexual desire that causes distress in premenopausal women — a condition doctors call hypoactive sexual desire disorder, or HSDD [3][7]. That approval covers one group of people, one dose, and one way of giving it: a single injection under the skin, used as needed.
Everything else you may read about PT-141 — using it in men, in postmenopausal women, for erectile problems, or for "performance" — sits outside that approval. Those uses are off-label or still being studied [1][7]. PT-141 acts on the brain's desire circuitry, not on blood flow, which makes it different from the more familiar erection pills [1]. The material sold online as a "research chemical" is not the approved medicine and is not made or checked the same way. This page, and what people report — including the downsides — on the effects page, reads the evidence plainly and recommends no dose to anyone.
What PT-141 is, in one paragraph
PT-141 is a synthetic cyclic peptide — seven amino acids joined in a ring — built as an analogue of alpha-MSH, a natural brain signalling molecule [1]. It switches on melanocortin receptors, mainly the type called MC4R (a receptor in the brain that helps set sexual motivation and appetite) [1]. Because it works centrally, in the hypothalamus and nearby circuits, it belongs to a different drug family than the erection medicines that act on blood vessels [1]. Its international nonproprietary name is bremelanotide; PT-141 and bremelanotide are the same molecule [3].
What the strongest studies measured
The headline evidence is human and large. Two identical Phase 3 randomized controlled trials — the RECONNECT program, with 1,267 premenopausal women who had HSDD — tested bremelanotide 1.75 mg given under the skin as needed. Both trials met their two main goals: sexual desire improved (integrated FSFI-desire score +0.35, P<.001) and the distress tied to low desire fell (integrated FSDS-DAO item-13 score −0.33, P<.001) over 24 weeks, versus placebo [3]. A 52-week follow-up of 684 women found those desire gains held and no new safety problems appeared; the most common side effects were nausea, flushing, and headache [4].
The mechanism has direct human evidence too. In a placebo-controlled brain-imaging study of 31 premenopausal women with HSDD, an MC4R agonist raised sexual desire for up to 24 hours and changed how the brain processed erotic images, strengthening connections between the amygdala and insula [5]. That is unusual: for a desire drug, the central mechanism has been watched happening in a scanner.
Who it is approved for — and who it is not
Approval is narrow on purpose. Bremelanotide is approved only for acquired, generalized HSDD in premenopausal women [7]. It is not approved for men, for postmenopausal women, for erectile dysfunction, or to enhance performance [7]. Early dose-escalation work in men with erectile dysfunction did show a dose-dependent erectile response [1], and a manufacturer began a Phase 2 study combining bremelanotide with an erection medicine for male erectile dysfunction in 2024 [14] — but that work is investigational and unapproved. We label every non-HSDD use as off-label or investigational throughout this site, because that is what the regulatory record says.
Where access fits in
The telehealth-access question — can a person get a sexual-health prescription remotely — is a fair one, and we treat it as a fact to explain rather than a service to offer. A peer-reviewed review has described how remote evaluation works in sexual medicine, including the workflow and the access considerations a clinician weighs [8], and international data tracked how telemedicine for sexual medicine grew during the COVID-19 pandemic [13]. We read PT-141 reviews and PT-141 benefits of the literature through that access lens, and link the underlying PT-141 research and PT-141 references so the claims are checkable. This is an editorial digest, not a clinic and not a pharmacy.